4342-50-1

Upstream product

• 6622-73-7 4-acetamidophenyl allyl ether 
• 99337-98-1 2-((1R,4R)-4-hydroxycyclohexyl) isoindoline-1,3-dione 
• 847416-23-3 2-((1R,4R)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)isoindoline-1,3-dione 

Downstream Products

• 950772-56-2 4-bromo-N₂-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine 
• 950772-55-1 N-(5-bromo-2-nitrophenyl)-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine 
• 950772-58-4 4-ethyl-N₂-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine 
• 950772-57-3 N-(5-ethenyl-2-nitrophenyl)-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine 
• 950772-59-5 N-(5-cyclopropyl-2-nitrophenyl)-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine 
• 950772-60-8 4-cyclopropyl-N₂-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine 
• 950772-09-5 trans-1-(4-propoxycylohexyl)-4-piperidone 

Relevant academic research and scientific papers

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

NITROGENOUS FIVE-MEMBERED RING COMPOUNDS

The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I] : wherein symbols in the formula have the following meanings;A: -CH2- or -S-,B: CH or N,R1: H, a lower alkyl group, etc.,X: a single bonding arm, -CO-, -Alk-CO-, -COCH2-, -Alk-O-, -O-CH2-, -SO2-, -S-, -COO-, -CON(R3)-, -Alk-CON(R3)-, -CON(R3)CH2-, -NHCH2-, etc.,R3: hydrogen atom or a lower alkyl group,Alk: a lower alkylene group, andR2: (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is -CO-, then B is N, or a pharmaceutically acceptable salt thereof.